September 2015

Scandinavian Micro Biodevices is proud to announce its participation in research project SMARTDIAGNOS. The project is partly funded by EU and received a 15 out of 15 score in the EU evaluation.  SMB is one of the lead partners in the consortium due to its unique set of integrated skills, and particularly because of the innovativeness level within micro fluidics technology.

The project SMARTDIAGNOS is led by DTU Nanotech and has the following partners:

  • Scandinavian Micro Biodevices

  • Cube Dx GmbH

  • DTU Fødevareinstituttet

  • TATAA Biocenter

  • Unilabs

  • Högskolan I Skövde

  • Charles University

  • Danube University Krems

  • Copenhagen Business School

  • Deutsches Institut für Normung e.V.

The project is aimed developing two products that will enable faster diagnosis of sepsis, where SMB will be responsible for the development of an emergency ward solution and Cube Dx for a laboratory solution. The SMARTDIAGNOS project receives an EU grant of 4 M€ (corresponding to 30 MDKK) and the partners will invest a similar amount making this a +8 M€ development project.

The project will advance sepsis diagnosis by simplifying clinical sample analysis methods and integrating the currently required numerous steps into a single streamlined device.

Sepsis is a potentially fatal condition that arises when the body’s response to an infection damages its own tissues and organs. It is mainly caused by bacteria and fungi, which spread through the blood circulation. It is one of the biggest public health issues worldwide due to its high incidence, mortality, human and economic cost. In the USA more people die from sepsis than from heart attack, lung cancer, colon cancer, or breast cancer. Early diagnosis is crucial to the management of sepsis, as every hour of delay of appropriate antibiotic therapy increases mortality by 5-10%.

Current diagnostic methods, including blood culture and different nucleic acid based multiplex technologies, are impaired by the significant time-delay of 1-3 days and low sensitivity of 30-50%. Hence there is an urgent need to develop new diagnostic tools that can provide more accurate and earlier sepsis diagnosis, so that patients with sepsis can be administered with prompt and correct initial antimicrobial treatment.

The project starts on 1 February 2016 and ends in 2020.